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Diabetes is extremely common, and its prevalence is rising
throughout the world. Associations between diabetes and
cardiovascular disease are well established, although the
mechanisms involved are incompletely understood. Diabe-
tes has been shown to be an important risk factor for heart
failure with either preserved or reduced ejection fraction,
and there is evidence that the extent of glucose elevation
relates directly to adverse outcomes in heart failure patients
(reviewed by Murarka and Movahed [1]).
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Activation of the renin-angiotensin (Ang) system (RAS)
is involved in the development and progression of heart
failure. Ang II, the main effector molecule of this system,
causes both vasoconstriction and salt and water retention. It
also stimulates cardiomyocyte hypertrophy and enhanced
cardiac fibroblast production of the extracellular matrix and
secondary growth factors that further promote cardiac
remodeling (2–4). The importance of the RAS in the
pathogenesis of heart failure has been confirmed by large-
scale clinical trials in human patients showing that targeting
Ang II by either preventing its formation or blocking its
interaction with the Ang type 1 (AT1) receptor inhibits
maladaptive cardiac remodeling and substantially improves
clinical outcomes (5–7).
Over time, it has become apparent that the RAS is much
more complex than was originally envisioned. Although the
classic RAS, in which circulating angiotensinogen released
from the liver is sequentially degraded by renin activity and
Ang-converting enzyme (ACE) to form Ang II, plays a
major role in maintaining cardiovascular homeostasis and
the pathogenesis of cardiovascular disease, other compo-
nents and pathways have been identified. These include
alterative enzymes (e.g., chymase) for converting Ang I to
Ang II, additional Ang II receptors (e.g., Ang type 2) and
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based RAS (4). Although of great theoretical interest, the
actual importance of many of these pathways (other than the
tissue-based RAS) in the pathogenesis of human cardiovas-
cular disease remains largely unproven. Thus, enthusiasm
for developing strategies targeting alternative RAS path-
ways with the hope that they could improve outcomes
beyond that seen with existing therapies has been restrained.
One of the more interesting recently identified alternative
pathways of the RAS involves a homologue of ACE that
has been termed ACE2. This enzyme has been identified in
many organs throughout the body, including liver, kidney,
brain, testes, blood vessels, and heart (8,9). The preferred
substrate appears to be Ang II, from which it cleaves the
C-terminal amino acid to form Ang-(1-7), a heptapeptide
that has vasodilatory and antigrowth properties. By its
ability to reduce Ang II while increasing Ang-(1-7) levels,
ACE2 has effects that would appear to help protect the
cardiovascular system in settings in which the RAS is
activated. In support of this is evidence that overexpression
of ACE2 has generally been found to have favorable effects
on cardiac structure and function (10–12). Germline abla-
tion of ACE2 has been associated with adverse effects on
cardiac function, but these results have not been consistent,
because they occurred spontaneously in some situations but
required pathological intervention in others (13–16). In an
experimental model of post–myocardial infarction remodel-
ing, inhibition of ACE2 enzyme activity had (mostly)
unfavorable effects on cardiac structure and function (17).
These findings suggest that strategies designed to enhance
ACE2 activity could be cardioprotective in cardiovascular
diseases in which the RAS is activated.
In this issue of the Journal, Dong et al. (18) present the
results of a series of experiments designed to assess the
effects of ACE2 overexpression in an experimental model of
diabetic cardiomyopathy. They generated a rat model of
diabetes by administering streptozotocin, and they con-
firmed previous reports that the diabetic rats developed
cardiac dilatation as well as systolic and diastolic dysfunc-
tion. A group of these diabetic rats was administered direct
intramyocardial injection of an adenoviral vector containing
complementary deoxyribonucleic acid for the murine ACE2
gene. Compared with appropriate control groups, the treated
rats had evidence of increased ACE2 enzyme activity, reduced
Ang II levels, and increased Ang-(1-7) levels. They further
demonstrated that ACE2 gene therapy was associated with
protection against maladaptive cardiac remodeling, a reduction
in intracardiac collagen accumulation and protection against
systolic and diastolic dysfunction.
The possible mechanisms by which ACE2 overexpression
exerted its cardioprotective effects in this experimental
model were also investigated. In a series of in vitro experi-
ments, the investigators showed that exposing cultured
neonatal rat cardiac fibroblasts and myocytes to media
containing increased glucose concentration increased Ang II
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ACE2 expression, reduced Ang II and increased Ang-(1-7)
levels were detected. Moreover, expression of collagen I,
collagen III, and transforming growth factor–beta and
3H-proline incorporation (as an indicator of collagen pro-
duction) were suppressed by ACE2 treatment in the cul-
tured fibroblasts. These antifibrotic effects were inhibited by
A779, a compound that acts as an Ang-(1-7) receptor
blocker, suggesting that they were mediated by the hepta-
peptide rather than by ACE2 effects on other pathways.
These findings are consistent with a previous study demon-
strating that Ang-(1-7) inhibits Ang II–stimulated produc-
tion of collagen and secondary growth factors in adult rat
cardiac fibroblasts (19).
The investigators also present evidence that the antifi-
brotic and other favorable cardiac effects of ACE2 exceed
those of the AT1 receptor blocker losartan. Potential expla-
nations for these findings include increased Ang-(1-7)
generation by ACE2 or the effects of the enzyme on other
peptides (e.g., apelin) that might favorably affect cardiac
structure and function. The possibility that overexpression
of ACE2 is more effective than AT1 receptor blockade by
virtue of its ability to protect against glucose-induced
increases in intracellular Ang II levels, however, seems
unlikely, because ACE2 is a type I ectoenzyme anchored to
the cell membrane with its catalytic domain(s) in the
extracellular space. Thus, like an AT1 receptor blocker,
ACE2’s effects are most likely related to events occurring on
the cell surface or surrounding milieu.
Although the precise mechanism(s) for the protective
effect of ACE2 that are reported are uncertain, these
findings raise the intriguing possibility that therapeutic
strategies designed to increase cardiac ACE2 activity could
help protect patients from some of the adverse effects of
diabetes on the heart. Because increased Ang II levels are
associated with many of the pathologic effects in this
experimental model of diabetes, the results also imply that
increasing ACE2 might be helpful in other cardiovascular
diseases in which RAS activation is involved. The activity of
ACE2 in the heart could be enhanced in several ways,
including increased expression or modified post-
translational processing of the enzyme. There is evidence
that AT1 receptor blockers increase ACE2 expression in
some experimental models, and it is possible that this
property may contribute to their beneficial effects. Discovery
of novel compounds with more robust effects on ACE2
expression would be helpful in determining if this strategy
could be effective in treating human cardiovascular disease.
Overexpression of ACE2 throughout the body, however,
could have systemic effects, including a reduction in blood
pressure, which may limit this approach. Reasonably selec-
tive cardiac expression of candidate genes appears to be
possible by means of gene transfer therapy using viral
vectors that contain cardiac specific promoters and avidly
transduce cardiomyocytes (20). This approach has been
successfully used to deliver complementary deoxyribonucleicacid from relevant genes to increase expression of key
proteins that are down-regulated in the failing heart. Pre-
liminary results from a study in which an adeno-associated
viral vector carrying recombinant human complementary
deoxyribonucleic acid for the sarco/endoplasmic reticulum
calcium ATPase-2 gene was administered by direct coro-
nary artery infusion to patients with advanced heart failure
are encouraging (21). Targeting cardiac fibroblasts with viral
vectors, however, is problematic, because there appears to be
considerably less uptake of viral particles by these cells
compared with that seen in cardiomyocytes that occupy a
much greater volume of the myocardium. Evidence of
cross-talk between cardiac cells demonstrated in this and
previous studies suggest that low uptake of viral particles in
fibroblasts may not be limiting. As shown in the present
study, overexpression of ACE2 in cardiomyocytes appears
to be able to influence cardiac fibroblast activities through
release of secondary signaling molecules. Further investiga-
tion of this approach seems warranted at this time.
Another possible approach to altering local ACE2 effects
in the heart would be to modify post-translational events
involved in regulating the enzyme’s availability. Because
ACE2 is a type I ectoenzyme anchored to the cell surface,
it is vulnerable to cleavage and release into the interstitial
space, from which it can then enter into the circulation.
There are reports of elevated levels of ACE2 in patients
with heart failure, although the significance of this finding is
uncertain. Modification of ACE2 that is designed to inhibit
cleavage from the cell surface is another potential strategy
that might be able to enhance local ACE2 within microen-
vironments of the heart. This is a more difficult prospect
than might be imagined, however, because ACE2 can be
cleaved at multiple sites, and more than 1 enzyme appears to
be capable of accomplishing this (22). Nonetheless, studies
designed to assess the effects of retaining cell-surface ACE2
on local concentrations of Ang peptides in the extracellular
milieu would be of interest.
Overall, the findings of Dong et al. (18) add to the
growing body of results indicating that increased ACE2
activity in the heart may be a useful strategy for preventing
or treating cardiovascular diseases, particularly those in
which RAS activation is involved. Although there are
existing therapeutic approaches targeting either ACE or the
AT1 receptor, it is becoming increasingly clear that the
complexity of the RAS may provide an avenue for additional
therapies that could further improve outcomes.
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